GlassScriptPhysician profile
Kylene A Polhamus
NPI 1427464890
$6,654.11
in general payments reported to CMS, 2019-2025
24 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $44.51 · 2021: $409 · 2022: $321 · 2023: $1,381 · 2024: $2,001 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,671 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $400 · Education: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,670.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $400.00 |
| Education | $217.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,361.16 | 2023-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $1,091.12 | 2019-2025 | Tryptyr, Hydrus Microstent, Rocklatan |
| Mallinckrodt Hospital Products INC. | $781.20 | 2021-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $598.52 | 2021-2025 | Cequa |
| Oyster Point Pharma, INC. | $508.09 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $370.78 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $334.11 | 2024-2025 | Vevye |
| Dompe US, INC. | $226.83 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $190.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $125.71 | 2022-2023 | |
| Johnson & Johnson Vision Care, INC. | $120.73 | 2023-2025 | Acuvue |
| Biotissue Holdings INC. | $110.12 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $109.98 | 2019-2025 | Eylea Hd |
| Allergan, INC. | $109.33 | 2019-2021 | |
| Abbvie INC. | $105.82 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $96.19 | 2019 | |
| Thea Pharma INC. | $79.08 | 2022-2023 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.88 | 2019 | |
| Staar Surgical Company | $77.23 | 2019 | |
| Shire North American Group INC | $55.52 | 2019 | |
| Glaukos Corporation | $52.33 | 2024-2025 | Idose, Idosetr, Istent Infinite |
| Horizon Therapeutics Plc | $30.40 | 2021-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $24.55 | 2025 | Yutiq |
| Sight Sciences, INC. | $15.90 | 2025 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylene Polhamus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.